ACADIA Pharmaceuticals Inc ACAD:NASDAQ

Last Price$39.95NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/18/19

Today's Change-0.03(0.08%)
Bid (Size)$40.00 (7)
Ask (Size)$40.55 (5)
Day Low / High$39.38 - 40.34
Volume3.1 M
 

View Biotechnology IndustryPeer Comparison as of 10/18/2019

 

ACADIA Pharmaceuticals Inc ( NASDAQ )

Price: $39.95
Change: -0.03 (0.08%)
Volume: 3.1 M
4:00PM ET 10/18/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $85.77
Change: -1.67 (1.91%)
Volume: 809.3 K
3:59PM ET 10/18/2019
 
 

Exelixis Inc ( NASDAQ )

Price: $16.42
Change: -0.58 (3.41%)
Volume: 2.6 M
4:00PM ET 10/18/2019
 
 

bluebird bio Inc ( NASDAQ )

Price: $89.53
Change: -1.80 (1.97%)
Volume: 894.4 K
3:59PM ET 10/18/2019
 

Read more news Recent News

ACADIA Pharmaceuticals Says Parkinson's Drug May Also Treat Sexual Dysfunction
11:47AM ET 10/07/2019 MT Newswires

ACADIA Pharmaceuticals (ACAD) said a secondary analysis of its Phase 2 CLARITY study evaluating pimavanserin showed the drug has the potential to improve...

MT Newswires After-Hours News Movers
5:40PM ET 10/03/2019 MT Newswires

Some of the stocks moving on news-driven events in Thursday's after-hours include: HRTX, -7.31% APVO, +5.84% OVID, -14.37% MEIP, +12.22% IDT, ...

ACADIA Pharma's Pimavanserin Trial in Dementia-Related Psychosis Accepted for Late-Breaking Presentation
5:07PM ET 10/03/2019 MT Newswires

ACADIA Pharmaceuticals (ACAD) said on Thursday its Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a...

Analyst Actions: ACADIA Pharmaceuticals Initiated at Outperform by RBC With $60 Price Target
9:01AM ET 10/01/2019 MT Newswires

ACADIA Pharmaceuticals (ACAD) received an outperform investment rating Tuesday from RBC Capital Markets as the firm said it believes the Street is...

Company Profile

Business DescriptionACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. View company web site for more details
Address3611 Valley Centre Drive
San Diego, California 92130-3331
Phone+1.858.558.2871
Number of Employees430
Recent SEC Filing10/17/20194
Chief Executive Officer & DirectorStephen R. Davis
PresidentSrdjan R. Stankovic
Chief Financial Officer & Executive Vice PresidentElena H. Ridloff
Chief Scientific Officer & Senior Vice PresidentEliseo Oreste Salinas

Company Highlights

Price Open$39.74
Previous Close$39.98
52 Week Range$14.01 - 44.85
Market Capitalization$5.8 B
Shares Outstanding144.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/30/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.97
Beta vs. S&P 500N/A
Revenue$223.8 M
Net Profit Margin-101.45%
Return on Equity-70.97%

Analyst Ratings as of 09/30/2019

Buy
11
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset